Yahoo Web Search

Search results

1. • Century-old vaccine found to protect type 1 diabetics from infectious diseases

     Medical Xpress· 3 days ago

     The 18-month Phase III trial, published in iScience, was conducted late in the US pandemic when...

2. • Trials that infected people with common colds can inform today’s COVID-19 challenge trials

     Nature· 5 days ago

     Letter to the Editor

3. • 

     TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?

     The Telegraph via Yahoo News· 5 days ago

     In the few minutes it takes to read this article, some 15 people are likely to have died from...

4. • 

     Could FLiRT Variants Cause Another Covid-19 Surge?

     Forbes· 4 days ago

     A new Covid-19 variant known as KP.2, or FLiRT, began to emerge in the United States in early March of this year. This dramatic rise signals that KP.2...

5. • CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

     Morningstar· 2 days ago

     Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1 ...

6. • Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

     WKRN Nashville· 1 day ago

     Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...

7. • 

     Iran's new president's link to COVID vaccine

     Newsweek· 5 days ago

     New interim Iranian President Mohammad Mokhber received scrutiny for his role in the lack of development of a domestic vaccine at the height of the...

8. • CureVac (NASDAQ:CVAC) Sees Large Volume Increase

     ETF DAILY NEWS· 1 day ago

     Shares of CureVac (NASDAQ:CVAC – Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 290,327 shares traded hands during mid-day trading, a decline of 63% from the ...

9. • Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and...

     The Yuma Sun· 5 days ago

     The efficacy of ARCT-154 against severe COVID-19 was 100 percent in healthy persons aged 18-59 and more...

10. • NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

      Morningstar· 2 days ago

      SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...